Dermatology

Top Medical News
Investigational drug scores big in mild-to-moderate AD, plaque psoriasis
Yesterday
The topical phosphodiesterase 4 inhibitor PF-07038124 is safe and helps lower disease activity in patients with mild-to-moderate atopic dermatitis (AD) and plaque psoriasis, according to the results of a phase IIa study.
Ertapenem infusion beneficial in hidradenitis suppurativa
6 days ago
Treatment with intravenous ertapenem yields improvements in the clinical and inflammatory markers of hidradenitis suppurativa (HS), according to a retrospective study.
Children of mothers with AD prone to develop AD, other allergic illness
22 Feb 2024
Children whose mothers have atopic dermatitis (AD) are likely to develop the same disease, while some develop other allergic illness (OAI) first, reports a study. This suggests that not everyone will follow the same sequential pathway.
5-year survival more likely in mBCC patients with nodal vs distant metastasis
21 Feb 2024
Among patients with metastatic basal cell carcinoma (mBCC), those with nodal disease appear to have a higher chance of remission, while individuals with distant metastasis tend to have persistent disease and subsequently die from it, a recent study reveals. However, the survival rates at 5 years surpass 50 percent even for those with stage IV disease.
Patch test a boon to dupilumab-treated patients
21 Feb 2024
A prospective, multicentre study has demonstrated the efficacy of patch tests (PTs) for patients who are being treated with dupilumab.
Smoking raises risk of death in early-stage melanoma
13 Feb 2024
Smokers who have received a diagnosis of early-stage melanoma are at increased risk of death, according to a study.
Oil palm pollen exposure may trigger, aggravate allergic diseases in Asians
Jairia Dela Cruz, 07 Feb 2024
Exposure to oil palm pollen poses a heightened risk of developing diseases such as asthma and allergic rhinitis in Asians or risk of exacerbations in those who have these diseases already, according to a study.
Special Reports
Starting JAK inhibitors in the Asian population based on real-world experience
14 Nov 2023
Dermatologists from Asia shared their clinical experience on the use of Janus kinase (JAK) inhibitors in atopic dermatitis (AD) and discussed approaches towards shared patient and doctor decision-making for treatment with JAK inhibitors. Dr Mark Tang (Mount Alvernia Hospital, Singapore) chaired the virtual meeting, which was attended by local dermatologists.
Meeting individual needs of patients with atopic dermatitis
Prof. Martin Steinhoff, Dr. Mahreen Ameen, Dr. Chih-Ho Hong, 06 Sep 2023

Atopic dermatitis (AD) is an inflammatory skin disease with complex aetiology and presentation. Globally, AD incidence is heterogeneous – it is higher in Africa and Oceania and lower in India and northeastern and eastern Europe, said Prof Martin Steinhoff, director, Translational Research Institute, Hamad Medical Corporation in Doha, Qatar, who chaired a Pfizer-sponsored symposium during WCD 2023.

AD has a variable course, and its heterogeneous presentation adds complexity to how the disease is managed. The burden of AD is the highest among all skin diseases, added Steinhoff. It has mental health manifestations such as anxiety and depression, chronic itch, fatigue, skin pain, and sleep disturbance. AD may also co-exist with other comorbidities that could impact patients’ general health. “We need to assess every patient carefully and manage them optimally,” he pointed out.

Steinhoff is joined by renowned experts Dr Mahreen Ameen, consultant dermatologist, Royal Free London NHS Foundation Trust, London, UK, and Dr Chih-Ho Hong, dermatologist, Saint Paul Hospital in Vancouver, Canada. Together, they shared four global cases of AD, including treatment options for patients.

Atopic dermatitis: Key drivers in making treatment decisions
Prof. Johannes Ring, Prof. Sonja Ständer, Prof. Zuotao Zhao, 05 Sep 2023
Atopic dermatitis (AD) is a chronic relapsing skin disease that requires long-term control. At the 25th World Congress of Dermatology (WCD) in Singapore, Professor Sonja Ständer, professor of dermatology and neurodermatology at the University Hospital Münster, Germany, and Professor Zuotao Zhao, dermatologist from the First Hospital, Peking University, Beijing, China, shared clinical approaches to managing patients with moderate-to-severe AD. The session was chaired by Professor Johannes Ring, director, Department of Dermatology and Allergy, Biederstein at the Technical University of Munich, Germany. Among the key topics discussed were the multifactorial nature of AD, its primary symptoms, and the various therapeutic options for itch relief.
Abrocitinib: The Novel Oral Treatment for Moderate-to-Severe Atopic Dermatitis
15 Jul 2022
Abrocitinib, the first janus kinase (JAK)1 inhibitor specifically indicated for the treatment of moderate-to-severe atopic dermatitis (AD), was recently approved in Singapore. During a webinar hosted by the Dermatological Society of Singapore, with the support of Pfizer, Professor Stephan Weidinger of University Hospital Scheswig-Holstein, Germany discussed several cases that exemplified appropriate patient selection for this novel agent.
Expert consensus: Patient profile should
guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
The gold standard amino acid formula for infants with cow’s milk allergy
24 Jul 2019
Cow’s milk allergy (CMA) is one of the most common forms of childhood food allergy, affecting 2% to 3% of infants in the first year of life.1 Although more prevalent in formula-fed infants, exclusively breast-fed infants can also develop CMA due to exposure to cow’s milk protein via the maternal diet.2,3 In general, up to 80% to 90% of children with CMA develop tolerance by three years of age.2
GP symposium 2019: Updates on the Use of Probiotics in Clinical Practice
Dr. Gwee Kok Ann, Dr. Warren Lee, Dr. Mark Tang, Dr. Lim Sanghyun, 24 Apr 2019
Modulation of gut microbiota with probiotics has been studied in a wide range of clinical settings, in the hope of achieving health benefits in the host. Under the auspices of the Asian GI Faculty, four experts discussed the role of probiotics in clinical practice at the recent IMPACT (Improving Medical Practice through Advancement in Clinical Treatment) GP symposium in Singapore sponsored by DCH Auriga.
Conference Reports
Brentuximab vedotin fares well for CTCL in real-world study
Audrey Abella, 26 Oct 2023
Interim findings from a prospective real-world study in Poland demonstrated favourable clinical outcomes and a tolerable safety profile for the CD30-directed antibody-drug conjugate brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).
How safe is long-term bimekizumab in plaque psoriasis patients?
Stephen Padilla, 24 Oct 2023
Treatment with bimekizumab (BKZ) for over 3 years does not result in the occurrence of new adverse events (AEs), demonstrating its positive safety profile in patients with moderate-to-severe plaque psoriasis, as shown by a pooled analysis of five phase III/IIIb trials presented at EADV 2023.
Risankizumab proven safe, effective in bio-naïve psoriasis patients
Stephen Padilla, 24 Oct 2023
Treatment with risankizumab (RZB) results in significantly lower absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at week 52 in bio-naïve psoriasis patients compared with other biologic therapies, according to the results of a 2-year interim analysis from the German cohort of the VALUE study, presented at EADV 2023.
Topical plant-based drug induces durable hair growth in children with moderate to severe AA
Jairia Dela Cruz, 24 Oct 2023
Twice-daily application of the botanical coacillium 22.25% cutaneous solution leads to significant hair growth in children and adolescents with moderate-to-severe alopecia areata (AA), with the improvement in hair loss sustained through months after treatment discontinuation, according to data from the phase II/III RAAINBOW trial.
Small wins for amlitelimab in STREAM-AD
Elvira Manzano, 23 Oct 2023
The experimental drug amlitelimab has scored positive outcomes in the double-blind, placebo-controlled phase IIb STREAM-AD study evaluating it as a treatment for moderate-to-severe atopic dermatitis (AD).
Nonsteroidal cream brings early relief in atopic dermatitis itch
Jairia Dela Cruz, 21 Oct 2023
In children and adults with moderate-to-severe atopic dermatitis, applying tapinarof cream 1% helps reduce itch within 24 hours, according to the results of the phase III trials ADORING 1 and 2.
Roflumilast serves up weight-loss benefit for patients with psoriasis
Jairia Dela Cruz, 20 Oct 2023
In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.